BioSpace News Archive

AIDS Healthcare Foundation sent an open letter to the heads of the Joint United Nations Programme on HIV/AIDS and the World Health Organization, urging the two institutions to conduct an audit of their HIV data over concerns that the global number of people on HIV treatment is overstated significantly.

Abbisko Therapeutics (HKEX code: 02256) announced that its investigational innovative CSF-1R inhibitor pimicotinib（ABSK021） has been granted orphan drug designation（ODD） by the European Medicines Agency (EMA) for the treatment of inoperable tenosynovial giant cell tumor (TGCT).

Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, outlined anticipated 2024 milestones ahead of its participation in the 42nd Annual J.P. Morgan Healthcare Conference.

Haystack Oncology, a Quest Diagnostics company, has entered into a collaboration with Alliance Foundation Trials, LLC for research use of Haystack Oncology’s personalized MRD technology to analyze therapeutic response and provide molecular insights for AFT’s interventional, randomized phase II clinical trial in patients with unresectable stage III non-small cell lung cancer.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, highlighted its recent progress and outlined 2024 strategic priorities across its pipeline of mRNA cell therapy product candidates.

Anavex Life Sciences Corp. announced it was granted new U.S. Patent No. 11,839,600 entitled “NEURODEVELOPMENTAL DISORDER THERAPY” from the United States Patent and Trademark Office for its patent application number 17/890,083.

Abeona Therapeutics Inc. announced that it has entered into a $50 million credit facility with the Avenue Venture Opportunities Fund, L.P.

Schrödinger, Inc., Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, provided an update on its progress across the business and announced its development and operational goals for 2024.

Jubilant Therapeutics Inc today announced preliminary safety, pharmacokinetic and initial efficacy results of of the Phase I trial in advanced cancer patients.

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced the initiation of enrollment for its Phase 1 clinical trial of FT825 / ONO-8250, a multiplexed-engineered, chimeric antigen receptor (CAR) T-cell product candidate targeting human epidermal growth factor receptor 2 (HER2).